louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02608619: Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
Official title: Pilot Study to Determine Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Erdheim-Chester Disease
Langerhans Cell Histiocytosis
Histiocytic Disorders
Keywords: 18F-fluorocholine
Pet imaging
Biopsy
15-268
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2015-11-20
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients for this study will be recruited by physicians from the Departments of Neurology.

Brief summary: The main purpose of this study is to discover how 18F-cholineFCH distributes in the body, and see if it can distinguish active histiocytes (tumor) from inflammatory (non- tumor) cells. This tracer has the potential to give the investigators' team more information when trying to identify the tumor cells that are most important to collect with biopsy. In addition, the study will measure levels of 18F-cholineFCH in the biopsy tissue.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years old
* Suspected but pathologically unconfirmed diagnosis of Erdheim-Chester disease or Langerhans cell histiocytosis or other histiocytic disorder on the basis of clinical diagnosis, radiologic features, or findings from prior biopsies

Or

* Confirmed diagnosis of Erdheim-Chester disease or Langerhans cell histiocytosis or other histiocytic disorder and requiring additional diagnostic imaging and biopsy to determine mutational status in order to determine therapeutic options.

Exclusion Criteria:

* Inability to undergo or cooperate with PET/CT scan (e.g., claustrophobia)
* Pregnant or nursing female

Primary outcomes:
measure: percentage of patients who successfully undergo paired biopsies
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memoral Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Eli Diamond, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01771419: Comparison Of Loop-Tip Wire Vs Tradictional Technique In The Cannulation Of The Common Bile Duct
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Post-ERCP Pancreatitis
Keywords: loop-tip
ERCP
cannulation of CBD
Lead sponsor: Hospital San Paolo
Sponsor class: OTHER
First posted: 2013-01-18
Enrollment: 320
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Selective cannulation of common bile duct (CBD) by insertion of a guide-wire seems to be associated with fewer complications and post-ERCP (Endoscopic retrograde cholangiopancreatography) pancreatitis (PEP) rate than the conventional biliary tree access with cannulotome (CT-25 Cook Medical) with contrast injection even if results are conflicting. the aim of our study is to test a new guide-wire (loop-tip wire), with a loop in the tip, for the prevention of PEP and biliary tree access, in PEP high-risk patients.


Eligibility criteria: Inclusion Criteria:

* high-risk patients for post-ERCP pancreatitis

Exclusion Criteria:

* age \< 18 years
* allargy to the contrast medium
* previous biliary or gastric surgery
* neoplastic patients
* previous biliary or pancreatic sphincterotomy

Primary outcomes:
measure: post ERCP pancreatitis rate
timeFrame: up to 4 weeks
Secondary outcomes:
measure: Number of attempts to obtain the cannulation of CBD and number of participants with adverse events as a measure of safety and tolerability
timeFrame: up to 4 weeks
Other outcomes:
Locations:
city: Milan
country: Italy
facility: San Paolo Hospital
Study officials:
References:
citation: Masci E, Mangiavillano B, Luigiano C, Bizzotto A, Limido E, Cantu P, Manes G, Viaggi P, Spinzi G, Radaelli F, Mariani A, Virgilio C, Alibrandi A, Testoni PA. Comparison between loop-tip guidewire-assisted and conventional endoscopic cannulation in high risk patients. Endosc Int Open. 2015 Oct;3(5):E464-70. doi: 10.1055/s-0034-1392879. Epub 2015 Sep 15.
Clinical trial NCT04494919: Novel Stent Placement Technique for Intestinal Stenosis Assisted by an Ultrafine Endoscope
Official title: Two Different Novel Stent Placement Technique for Intestinal Stenosis Assisted by an Ultrafine Endoscope
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Carcinoma
Lead sponsor: Ningbo No. 1 Hospital
Sponsor class: OTHER
First posted: 2020-07-31
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with colorectal stricture underwent novel intestinal stent implantation methods assised by ultrafine endoscope.

Brief summary: Colorectal cancer is the third most common cancer worldwide and results in 8-25% acute malignant bowel obstruction. Since Dohmoto et al. first applied and reported the self-expanding metal stents (SEMS) in the treatment of colorectal stenosis, they have been widely used not only as an alternative treatment as a bridge to surgery (BTS), but also as a mean of palliative option for stenosing lumen in clinical practice. Numerous publications have reported that the stent placement technique showed 75% to 100% technical success rates and 84% to 100% clinical success rates. However, it is sometimes difficult to place due to the distorted anatomy or acute angulations in patients and other conditions with poor endoscopic visualization with the normal colonoscope. The aims of this study were to present our results with two novel SEMS implantation techniques.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years old
* Patients with colorectal cancer stenosis
* Patients with intestinal stent implantation in digital subtraction angiography room

Exclusion Criteria:

* Patients undergoing conventional intestinal stent implantation

Primary outcomes:
measure: The technical success rate
timeFrame: 1 hour
Secondary outcomes:
measure: The clinical success rate
timeFrame: 24 hours
measure: The adverse events rate
timeFrame: 2 year
Other outcomes:
Locations:
city: Ningbo
country: China
facility: Ningbo first hospital
state: Zhejiang
Study officials:
References:
Clinical trial NCT07023419: Psychiatric Disorders in Addiction - Interest of Screening and Influence on Relapse
Official title: Psychiatric Disorders in Addiction - Interest of Screening and Influence on Relapse
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Psychiatric Disorders
Keywords: Psychiatric Disorders
Addiction
Complex detox
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2025-06-17
Enrollment: 100
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subject aged ≥16 and having been hospitalized in the complex withdrawal unit of the Strasbourg psychiatric clinic during the period from January 1, 2024 to November 1, 2024

Brief summary: In complex detoxification hospital units, patients receive a common care system (interviews, therapeutic workshops, support for discharges, etc.). In the event of a relapse during hospitalization, i.e., a relapse into addiction, hospital care is called into question, and discharge is generally considered. A key care issue is therefore to prevent these relapses by identifying risk profiles to strengthen their management. According to studies, psychiatric diagnoses increase the risk of relapse, but we do not fully understand which ones or to what extent.

The objective of this study is to analyze the influence of psychiatric diagnoses on the risk of relapse. This would allow for adapting the care of these patients to reduce this risk. The investigators are also seeking to study the value of screening questionnaires in improving the reliability of psychiatric diagnoses.


Eligibility criteria: Inclusion Criteria:

* Subject aged ≥16
* Having been hospitalized in the complex withdrawal unit of the Strasbourg psychiatric clinic during the period from January 1, 2024 to November 1, 2024

Exclusion Criteria:

* Refusal to participate in the study

Primary outcomes:
measure: Insomnia Severity Score (ISI)
timeFrame: At 22 months
measure: Depression Scale Score (PHQ 9)
timeFrame: At 22 months
measure: Anxiety score (GAD-7)
timeFrame: At 22 months
measure: Posttraumatic Stress Disorder Score (PCL-5)
timeFrame: At 22 months
measure: Addictions Score (DAST-10)
timeFrame: At 22 months
measure: ADHD Score
timeFrame: At 22 months
measure: Autism Score (RAADS-14)
timeFrame: At 22 months
measure: Emotion Dysregulation Score (DERS-16)
timeFrame: At 22 months
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service d'Addictologie - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT00346619: Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults
Official title: Investigating the Time of Nelfinavir Treatment Necessary for an Increase in Thymic Naive T Cells in Adults.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Immune Response
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2006-06-30
Enrollment: 25
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Our group has shown that HAART increases the thymic production of naïve T cells in the healthy adult, thereby boosting the immune system. We propose to investigate the amount of and length of Nelfinavir therapy necessary to increase those cells in adults. Subjects will be treated with Nelfinavir, and blood will be sampled at variable times to determine the immune response in peripheral blood.

Detailed description: Blood will be collected at several time points during the study. DNA will be isolated from peripheral blood lymphocytes (PBL) and assessed for signal point (sj) TREC content relative to genomic CCR5 copies by real time PCR in a spectoflourometic thermal cycler. TREC values will be expressed as TREC copy number per copies of CCR5 or TREC/PBLs.

We anticipate that we will confirm our previous observations that nelfinavir therapy will increase TRECs, indicating naive T cell production from the thymus. The proposed study will determine the time course of the anticipated increase in TREC/PBLs.

Eligibility criteria: Healthy individuals between the ages of 20 and 100. Exclusion criteria include the following: HIV, HBV/HCV positive, known sensitivity to protease inhibitors, oral intake contraindicated, diabetes mellitus diagnosed within the last six months, and any of the following medications: cisapride, amiodarone, terfenadine, rifampin/rifabutin, phenobarbital, pinozide, St. John's wort, ergot derivatives, quinidine, astemazole, carbemazapine, phenytoin, midazolam, triazolam, and simvastatin.

Primary outcomes:
measure: Will confirm that HIV protease inhibitors increase thymic naïve T-cell production and determine the dose and time needed to increase thymic T-cell production in adults.
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Stacey R. Vlahakis, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rizza SR, Tangalos EG, McClees MD, Strausbauch MA, Targonski PV, McKean DJ, Wettstein PJ, Badley AD. Nelfinavir monotherapy increases naive T-cell numbers in HIV-negative healthy young adults. Front Biosci. 2008 Jan 1;13:1605-9. doi: 10.2741/2784.
Clinical trial NCT01358019: A Study of LY2523355 in Patients With Solid Cancer
Official title: A Phase 1 Study of LY2523355 in Patients With Solid Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumors
Lead sponsor: Kyowa Kirin Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2011-05-23
Enrollment: 18
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to examine a recommended dose for subsequent phase trial(s), by the observation of the safety and toxicity profiles of LY2523355 in patients with advanced and/or metastatic cancer. The secondary objectives are to study the pharmacokinetics and antitumor effect.


Eligibility criteria: Inclusion Criteria:

* Histological and/or cytological evidence of solid tumors
* A diagnosis of advanced and/or metastatic solid tumors
* Patients who are refractory to standard therapy or for which no proven effective therapy exists
* Written informed consent
* Appropriate bone marrow, hepatic and renal functions
* ECOG PS =\< 1

Exclusion Criteria:

* Have serious preexisting complication
* Have active infection which requires intravenous antibiotics
* Have symptomatic central nervous system metastases
* Have current acute or chronic leukemia
* Have had an autologous or allogenic hematopoietic stem cell transplantation
* Have active multiple cancers

Primary outcomes:
measure: Dose limiting toxicity based on the Common Terminology Criteria for Adverse Events v4.0
measure: Number of patients with adverse events
Secondary outcomes:
measure: Pharmacokinetics
measure: Antitumor effect
Other outcomes:
Locations:
city: Tokyo
country: Japan
Study officials:
affiliation: Kyowa Kirin Co., Ltd.
name: Senior Manager
role: STUDY_DIRECTOR
References:
citation: Wakui H, Yamamoto N, Kitazono S, Mizugaki H, Nakamichi S, Fujiwara Y, Nokihara H, Yamada Y, Suzuki K, Kanda H, Akinaga S, Tamura T. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):15-23. doi: 10.1007/s00280-014-2467-z. Epub 2014 Apr 22.
Clinical trial NCT03809819: Urogynecological and Sexual Functions After Vecchietti Operation
Official title: Urogynecological and Sexual Functions After Laparoscopic Vecchietti Vaginoplasty
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mayer-Rokitansky-Kuster Syndrome
Keywords: Laparoscopic Vecchietti vaginoplasty
sexual function
urinary incontinence
Lead sponsor: Medical University of Lublin
Sponsor class: OTHER
First posted: 2019-01-18
Enrollment: 26
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Thirteen patients with MRKHS who underwent laparoscopic Vecchietti vaginoplasty were included. A control group of 13 age-matched, childless, sexually active women were examined during the same period

Brief summary: The aim of this study was to establish the urogynecological and sexual functions after Vecchietti operation.

Detailed description: Thirteen patients with MRKHS who underwent laparoscopic Vecchietti vaginoplasty were included. A control group of 13 age-matched, childless, sexually active women were examined during the same period. All patients underwent the basic evaluation of anatomical outcomes. Sexual outcomes were established by polish validated FSFI questionnaire. Continence status was assessed by polish validated UDI-6 and IIQ-7 questionnaires. The UDI-6 is subdivided in three domains: stress incontinence, irritative and obstructive discomfort. The IIQ-7 measures the implications of urinary incontinence for normal daily functioning.

Eligibility criteria: Inclusion Criteria:

* patients with MRKHS who underwent laparoscopic Vecchietti vaginoplasty
* control group of 13 age-matched, childless, sexually active women

Exclusion Criteria:

* unability to understand informed consent

Primary outcomes:
measure: sexual functions after Vecchietti operation
timeFrame: 8 years
measure: Urinary incontinence after Vecchietti operation
timeFrame: 8 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Medical University in Lublin
name: Paweł Miotła, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Adamiak-Godlewska A, Skorupska K, Rechberger T, Romanek-Piva K, Miotla P. Urogynecological and Sexual Functions after Vecchietti Reconstructive Surgery. Biomed Res Int. 2019 Feb 25;2019:2360185. doi: 10.1155/2019/2360185. eCollection 2019.
Clinical trial NCT00132119: Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Pathological Gambling
Lead sponsor: Somaxon Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2005-08-19
Enrollment: 233
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.

Detailed description: Randomized, double-blind, placebo-controlled, parallel-group, multi-centered, outpatient study to assess the efficacy, safety and tolerability of two doses of nalmefene in patients with current diagnosis of pathological gambling.

Eligibility criteria: Inclusion Criteria:

* Current diagnosis of pathological gambling as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

Primary outcomes:
measure: Assess efficacy in treatment of pathological gambling
Secondary outcomes:
measure: Evaluate safety and tolerability in treatment of pathological gambling
Other outcomes:
Locations:
Study officials:
affiliation: Somaxon Pharmaceuticals CMO
name: Philip Jochelson, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00516919: Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons
Official title: Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Obesity
Binge Eating
Keywords: Obesity
Binge Eating
Monolingual Hispanic Persons
Orlistat
Behavioral Weight Loss Treatment
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: Donaghue Medical Research Foundation
First posted: 2007-08-16
Enrollment: 79
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a research study designed to examine the effectiveness of an obesity medication (orlistat) given in addition to behavioral weight loss therapy. Participants will be obese monolingual (Spanish-speaking only) men and women.


Eligibility criteria: Inclusion Criteria:

* Monolingual Spanish Speaking
* Obese (BMI \>= 30)

Exclusion Criteria:

* Pregnancy
* Current cardiac disease
* Serious neurologic illnesses

Primary outcomes:
measure: Participant BMI
timeFrame: 4 months and 6 month follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Hispanic Clinic of the Connecticut Mental Health Center
state: Connecticut
city: New Haven
country: United States
facility: Yale Department of Psychiatry
state: Connecticut
Study officials:
affiliation: Yale University
name: Carlos M Grilo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Grilo CM, Kerrigan SG, Lydecker JA, White MA. Physical activity changes during behavioral weight loss treatment by Latinx patients with obesity with and without binge eating disorder. Obesity (Silver Spring). 2021 Dec;29(12):2026-2034. doi: 10.1002/oby.23278. Epub 2021 Sep 28.
citation: Grilo CM, White MA. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. Behav Res Ther. 2013 Mar;51(3):167-75. doi: 10.1016/j.brat.2013.01.002. Epub 2013 Jan 18.
Clinical trial NCT02495519: A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
Official title: A Phase II Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Fibromatosis
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2015-07-13
Enrollment: 21
Sex: ALL
Minimum age (years): 10
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Aggressive fibromatosis (AF, also known as desmoid tumor) is a fibroproliferative neoplasm that typically arises in the abdomen but can develop at other anatomic sites, most commonly in the extremities. These tumors have a relatively high local failure rate after primary treatment using surgery and/or radiotherapy, and although rarely giving rise to distant metastases, can be multifocal and, therefore, not surgically resectable. Moreover, tumor may recur adjacent to the site of surgical resection, underscoring the limitations of surgery in the palliative setting. Therefore, effective medical therapies for AF are needed to maintain quality of life and prolong survival.The goal of the current study was to better define the activity of imatinib in the treatment of AF and to determine the molecular basis for response/nonresponse


Eligibility criteria: Inclusion Criteria:

1. Written consent;
2. Age ≥ 10 years;
3. Eastern Cooperative Oncology Group Performance status ≤ 2;
4. Histologically confirmed desmoid tumor;
5. Disease progression after local treatment
6. Measurable target lesion (RECIST criteria) ;
7. Adequate hematological, renal and liver functions :

Exclusion Criteria:

1. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ.
2. Pregnant or lactating female
3. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study

Primary outcomes:
measure: non-progressive rate
timeFrame: 16weeks
Secondary outcomes:
measure: overall survival
timeFrame: 16 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System
Study officials:
affiliation: Severance Hospital, Yonsei University Health System
name: Hyo Song Kim
role: PRINCIPAL_INVESTIGATOR
References: